Medical Condition News

RSS

Svelte Medical completes 6 month follow up in initial Acrobat angioplasty system clinical trial

Svelte™ Medical Systems, Inc. is pleased to announce that it has completed 6 month follow up in its initial clinical trial with the Svelte Acrobat angioplasty system.

21 Mar 2011

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

If a big bunch of your brain cells suddenly went rogue and decided to become fat cells, it could cloud your decision-making capacity a bit. Fortunately, early in an organism's development, cells make firm and more-or-less permanent decisions about whether they will live their lives as, say, skin cells, brain cells or, well, fat cells.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

SLEH treats irregular heartbeat with novel minimally invasive cold cryoballoon technology

A physician affiliated with Texas Heart® Institute (THI) at St. Luke's Episcopal Hospital (SLEH) is the first in Houston and among the first in the nation to treat patients for an irregular heartbeat with a new, minimally invasive cryoballoon technology that uses cold rather than heat to interrupt faulty electrical circuits in the heart.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Innovative algorithm for AEDs distinguishes betweeen adult and child arrhythmias

Ventricular Fibrillation (VF) is a series of intense and disordered contractions of the ventricles (they are located in the lower part of the heart). In 40 % of respiratory arrests suffered outside a hospital, it was shown that the first cardiac rhythm corresponds to VF, and the only manner to combat it is with electric discharges provided by defibrillation. This

21 Mar 2011

Research outlines how cilia disease gene products regulate early cilium formation

An international collaboration jointly led by University College Dublin, University of Alabama and Simon Fraser University, British Columbia has outlined in the Journal of Cell Biology how cilia disease gene products regulate important aspects of early cilium formation and the integrity of the ciliary transport gate.

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

United Therapeutics Corporation announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

21 Mar 2011

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.

21 Mar 2011

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month review timeline is consistent with review as a Class II resubmission.

21 Mar 2011

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher T. Nguyen will hold an oral presentation on a study titled "Mandibular Changes Produced by Skeletal Anchorage Assisted Orthopedic Traction."

21 Mar 2011

Physical ill-health reduces life expectancy of people with severe mental illness

Physical ill-health is rife among the severely mentally ill in Britain, according to new research published today by the University of East Anglia (UEA).

21 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

21 Mar 2011

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Chronic fatigue syndrome (CFS) is characterized by unexplained and debilitating tiredness and is associated with headaches, disrupted sleep, muscle pain and difficulty in concentrating. New research published by BioMed Central's open access journal BMC Medicine shows that ethnicity, depression, lack of exercise or social support, and social difficulties are major risk factors for CFS.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

Researchers baffled with increase in migraine rates

Migraine rates in a comprehensive Norwegian health study have climbed by 1% in a decade -- that may not sound like much, but in the Norwegian context, it means 45,000 more migraine sufferers -- and if the trend were to hold for the European Union, that would be an additional 5 million more people plagued by migraines. Researchers at the Norwegian University of Science and Technology (NTNU) are baffled by the cause of this trend.

21 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

Researchers discover 'broad spectrum' cancer suppressor gene

Portuguese researchers have discovered a "broad spectrum" cancer suppressor gene - called LRP1B - which acts by removing proteins crucial for cancer development from the tumour environment. The fact that LRP1B does not act on the tumour itself (in this study thyroid tumours) but, instead, on molecules which are known to be important to many different cancers is what makes it so interesting.

21 Mar 2011

Medical Condition News

Svelte Medical completes 6 month follow up in initial Acrobat angioplasty system clinical trial

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

Sarsia Seed provides follow-up funding for APIM Therapeutics

SLEH treats irregular heartbeat with novel minimally invasive cold cryoballoon technology

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Innovative algorithm for AEDs distinguishes betweeen adult and child arrhythmias

Research outlines how cilia disease gene products regulate early cilium formation

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Physical ill-health reduces life expectancy of people with severe mental illness

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

Ethnicity, depression, lack of exercise are major risk factors for chronic fatigue syndrome

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Researchers baffled with increase in migraine rates

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

Researchers discover 'broad spectrum' cancer suppressor gene

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News